Boehringer Ingelheim Realizes Key Launches in Late-Stage Pipeline, Sees 7.3% Sales Rise in Successful 2025

(SeaPRwire) –   Target audience: global business, financial, and trade media

• HERNEXEOS® (zongertinib) and JASCAYD® (nerandomilast) were launched in the second half of 2025
• Group net sales rose by 7.3%* to EUR 27.8 billion in 2025
• R&D investments increased to EUR 6.4 billion, which equals 22.9% of the group’s net sales
• The company reached 70 million patients in 2025, an increase from 66 million in 2024

Ingelheim, March 25, 2026 – Boehringer Ingelheim effectively followed through on key product launches in its Human Pharma division in 2025, introducing two medications with FDA Breakthrough Therapy status for lung cancer and pulmonary fibrosis to the market during the second half of the year. For the full year, group net sales climbed 7.3%* to EUR 27.8 billion, backed by strong performance from both the Human Pharma and Animal Health segments. In 2025, Boehringer boosted its Research and Development (R&D) spending to EUR 6.4 billion, which accounts for 22.9% of the group’s net sales. The company provided access to its innovative medicines to 70 million patients in 2025—more than ever before.

“The year 2025 highlighted the robustness of our pipeline and emphasized the value of our long-term R&D investments.

With two newly launched treatments in oncology and respiratory care, we are meeting critical unmet medical needs for patients while also refreshing our product portfolio. Our pipeline puts us in a strong position to keep making meaningful contributions across key disease areas and to deliver innovative therapies to an even larger number of patients,” stated Shashank Deshpande, Chairman of the Board of Managing Directors and head of Human Pharma. “As 2026 progresses with key Phase III trials, data readouts, and upcoming launches, we aim to enhance the lives of patients, animals, and communities around the globe.”

Frank Hübler, Member of the Board of Managing Directors in charge of Finance, added: “Despite volatile market conditions and regional hurdles, our business showed resilience by focusing on our core strengths: delivering more medications to patients and animals. We are investing more heavily in innovation than ever before, which mirrors our ambitions for the coming years.”

Human Pharma: JARDIANCE® (empagliflozin) and OFEV® (nintedanib) maintain growth momentum; HERNEXEOS® and JASCAYD® introduced to market

Human Pharma sales increased by 7.4%* to EUR 22.7 billion, driven by solid results from its core brands. JARDIANCE®, used to treat chronic kidney disease, type 2 diabetes, and heart failure, saw an 8.7%* rise in sales to EUR 8.8 billion. OFEV®, which treats idiopathic pulmonary fibrosis and other progressive fibrosing interstitial lung diseases, recorded a 5.4%* sales growth to EUR 3.8 billion.

Boehringer Ingelheim expanded its product lineup in 2025 with two innovative therapies: HERNEXEOS®—an oral treatment for HER2-mutant advanced non-small cell lung cancer—was rolled out in the U.S. in August 2025. The company also launched JASCAYD®, which received approval in the U.S. and China for idiopathic pulmonary fibrosis (IPF) in October 2025, and for progressive pulmonary fibrosis (PPF) in December 2025. JASCAYD® is the first new innovative therapy for IPF to enter the market in over a decade.

Human Pharma R&D investments totaled EUR 5.8 billion, or 27.4% of the unit’s net sales. The company continued to progress its pipeline across cardiovascular, renal, and metabolic diseases (CRM), oncology, respiratory and immunology, mental health, and eye health. Currently, the pipeline features over 80 projects, including more than 50 new molecular entities. Ongoing developments in Boehringer’s expanding mid- and late-stage pipeline are paving the way for a steady stream of potential launches, positioning the company to create transformative benefits for patients in the future.

Animal Health: Stopping the spread of transboundary animal diseases

In 2025, the Animal Health division showed resilience and positive impact, with sales increasing by 6.5%* to EUR 4.9 billion. Growth was fueled by the pet parasiticide and therapeutic, poultry, and ruminant segments—NEXGARD® saw an 8.5%* sales increase to EUR 1.4 billion, solidifying its status as the industry’s best-selling parasiticide brand.

The company collaborated closely with farmers, veterinarians, and governments to help fight livestock diseases like avian influenza, foot-and-mouth disease, and bluetongue virus. Boehringer obtained EU Marketing Authorization under Exceptional Circumstances for two poultry vaccines, aiding producers in maintaining healthy flocks and enhancing preparedness for avian influenza outbreaks. Alongside the VAXXINACT® H5 avian influenza vaccine, VAXXITEK® HVT+IBD+H5 is a new trivalent vaccine that protects chickens and turkeys against Marek’s disease, Infectious Bursal Disease, and H5 avian influenza.

Outlook

For 2026, Boehringer plans to build upon the momentum of recent years, with ongoing progress in both the Animal Health and Human Pharma pipelines, and key milestones expected especially in CRM, oncology, and eye health.

* Sales growth figures are adjusted for currency fluctuations

Boehringer Ingelheim
Boehringer Ingelheim is a biopharmaceutical firm operating in both human and animal health sectors. As one of the industry’s leading R&D investors, the company prioritizes developing innovative treatments that enhance and prolong lives in areas where medical needs are unmet. Founded in 1885 and remaining independent ever since, Boehringer adopts a long-term approach, integrating sustainability throughout its entire value chain. Our roughly 54,300 employees serve more than 130 markets to create a healthier, more sustainable future. For more information, visit www.boehringer-ingelheim.com.

Attachment

• Boehringer biopharma production